Beximco Pharmaceuticals (DHA:BXPHARMA) Cyclically Adjusted FCF per Share: BDT0.81 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:BXPHARMA Beximco Pharmaceuticals PLC DHA:BXPHARMA
93 GF Score
Price BDT144.20
GF Value BDT129.17
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Cyclically Adjusted FCF per Share?

Beximco Pharmaceuticals DHA:BXPHARMA +0.84% 93 Cyclically Adjusted FCF per Share is BDT0.81 as of Mar. 2026. GuruFocus rates DHA:BXPHARMA with a GF Score™ of 93/100 and a GF Value™ of BDT129.17 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was BDT-0.663. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is BDT0.81 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beximco Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 224.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Beximco Pharmaceuticals was 68.40% per year. The lowest was 44.90% per year. And the median was 47.85% per year.

As of today (2026-08-26), Beximco Pharmaceuticals's current stock price is BDT144.20. Beximco Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was BDT0.81. Beximco Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 178.02.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Beximco Pharmaceuticals was 1015.83. The lowest was 114.49. And the median was 295.69.


Beximco Pharmaceuticals  (DHA:BXPHARMA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Beximco Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=144.20/0.81
=178.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Beximco Pharmaceuticals was 1015.83. The lowest was 114.49. And the median was 295.69.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Beximco Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Beximco Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.11 -0.39 -0.06 0.14

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.14 0.67 0.89 0.81

DHA:BXPHARMA vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


DHA:BXPHARMA
93GF Score
Beximco Pharmaceuticals PLC DHA:BXPHARMA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.663/330.2130*330.2130
=-0.663

Current CPI (Mar. 2026) = 330.2130.

Beximco Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.000 241.018 0.000
201609 0.754 241.428 1.031
201612 -0.532 241.432 -0.728
201703 -0.709 243.801 -0.960
201706 -0.579 244.955 -0.781
201709 -0.094 246.819 -0.126
201712 -1.879 246.524 -2.517
201803 -3.158 249.554 -4.179
201806 -2.131 251.989 -2.793
201809 0.205 252.439 0.268
201812 -0.282 251.233 -0.371
201903 -2.443 254.202 -3.174
201906 -5.756 256.143 -7.420
201909 3.185 256.759 4.096
201912 1.842 256.974 2.367
202003 -0.754 258.115 -0.965
202006 2.732 257.797 3.499
202009 1.457 260.280 1.848
202012 1.493 260.474 1.893
202103 2.538 264.877 3.164
202106 2.279 271.696 2.770
202109 2.617 274.310 3.150
202112 1.874 278.802 2.220
202203 0.274 287.504 0.315
202206 0.334 296.311 0.372
202209 0.005 296.808 0.006
202212 -1.555 296.797 -1.730
202303 3.213 301.836 3.515
202306 -1.867 305.109 -2.021
202309 4.701 307.789 5.043
202312 -1.236 306.746 -1.331
202403 -0.932 312.332 -0.985
202406 -1.472 314.175 -1.547
202409 3.046 315.301 3.190
202412 -0.627 315.605 -0.656
202503 -1.634 319.799 -1.687
202506 -1.445 322.561 -1.479
202509 3.722 324.800 3.784
202512 1.495 324.054 1.523
202603 -0.663 330.213 -0.663

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of BDT0.81 mean?
Beximco Pharmaceuticals (DHA:BXPHARMA) has a Cyclically Adjusted FCF per Share of BDT0.81 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Beximco Pharmaceuticals' current Cyclically Adjusted FCF per Share is BDT0.81. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cyclically Adjusted FCF per Share of BDT0.81 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cyclically Adjusted FCF per Share is BDT0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (DHA:BXPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT129.17, compared to a current price of BDT144.20 — trading 11.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is BDT0.81. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Beximco Pharmaceuticals (DHA:BXPHARMA), the current Cyclically Adjusted FCF per Share is BDT0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (DHA:BXPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of BDT144.20 is trading 11.6% above its estimated GF Value™ of BDT129.17. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for DHA:BXPHARMA:

  • Cyclically Adjusted FCF per Share: BDT0.81
  • GF Value™: BDT129.17 vs. price of BDT144.20 (11.6% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the DHA:BXPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beximco Pharmaceuticals Business Description

Other Exchanges BXP:UKR2WA:Germany
Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
93GF Score

Get the complete analysis for DHA:BXPHARMA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT144.20
Price
BDT129.17
GF Value